Skip to main content
. 2012 Mar 20;184(5):543–549. doi: 10.1503/cmaj.110493

Figure 1:

Figure 1:

Number of federal court cases in which a generic drug firm was either an applicant or a respondent, 1970–2010. The line represents the introduction of Notice of Complience regulations in 1993. Source: court index and docket of federal court and federal court of appeal (http://cas-ncr-nter03.cas-satj.gc.ca/IndexingQueries/infp_queries_e.php).